secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apexigen, Inc. (—)
CIK:        0001814140
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0000950170-23-044038
Event type: m_and_a
Sentiment:  negative
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apexigen completes merger with Pyxis Oncology; becomes wholly owned subsidiary
------------------------------------------------------------------------------

- Each Apexigen share converted into 0.1725 Pyxis Oncology common shares; ~4.34M Pyxis shares issued.
- All Apexigen directors and officers resigned; former director Dr. Jakob Dupont joined Pyxis board.
- Apexigen common stock and warrants delisted from Nasdaq; Form 25 and Form 15 filings to follow.
- Outstanding Apexigen options, RSUs, and warrants assumed and converted using the 0.1725 exchange ratio.
- Apexigen's charter and bylaws amended effective with the merger; company now a private Pyxis subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814140/000095017023044038/0000950170-23-044038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814140/000095017023044038/apgn-20230823.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-044038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer